Dublin, Dec. 16, 2020 (GLOBE NEWSWIRE) -- The "Global Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular Diseases, Diabetes), Type (Disposable, Reusable), Route of Administration (Subcutaneous, Intramuscular), End-user (Hospital) and Region - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46 billion in 2020, at a CAGR of 17.9% from 2020 to 2025.
Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favorable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.
On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices.
The rheumatoid arthritis segment accounted for the largest share of the autoinjectors market in 2020
Based on therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, and other therapies (cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest market share of autoinjectors market. The large share of this segment is mainly due to the high prevalence of rheumatoid arthritis.
The subcutaneous segment is projected to grow at the highest CAGR during the forecast period
Based on route of administration, the autoinjectors market is segmented into intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anemia, and cancer. The subcutaneous segment is projected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.
North America accounted for the largest share of the autoinjectors market in 2020
The autoinjectors market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Latin America, and the Middle East & Africa. North America was the largest regional market for autoinjectors. Growth in the North American market is majorly driven by factors such as the rising incidence of anaphylaxis and the presence of favorable reimbursements. Moreover, the US and Canada are developed economies with high awareness and adoption rates for advanced devices such as autoinjectors, which is beneficial for market growth. Furthermore, other micro-economic indicators such as rising healthcare expenditures, high affordability rate, and the improving regulatory scenario are also major factors contributing to market growth.
Growing Prevalence of Targeted Therapies
Rising Incidence of Anaphylaxis
Increasing Number of Regulatory Approvals
Availability of Generic Versions of Autoinjectors
Favorable Reimbursements and Government Support
Ease of Use Increasing the Preference for Self-Administration
Alternative Drug Delivery Modes
Research, Development, and Launch of Oral Diabetic Agents and Oral Insulin
Development of Nasal Epinephrine Sprays
Patent Expiry of Biologics to Drive the Demand for Biosimilars
Need to Limit Patient Visits and Physical Contact
Development of Autoinjectors for Multiple Drug Viscosities
Lack of Proper Training for Using Autoinjectors
COVID-19 Impact on the Autoinjectors Market
Average Selling Price Trends
Value Chain Analysis
Antares Pharma, Inc.
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche
Johnson & Johnson (J&J)
Medeca Pharma AB
Meridian Medical Technologies, Inc. (A Pfizer Company)
Teva Pharmaceutical Industries
For more information about this report visit https://www.researchandmarkets.com/r/1nppcr
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900